A.-C. Piguet

1.3k total citations · 2 hit papers
7 papers, 1.0k citations indexed

About

A.-C. Piguet is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, A.-C. Piguet has authored 7 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Epidemiology, 3 papers in Hepatology and 2 papers in Molecular Biology. Recurrent topics in A.-C. Piguet's work include Liver Disease Diagnosis and Treatment (3 papers), Cancer Mechanisms and Therapy (2 papers) and Liver physiology and pathology (2 papers). A.-C. Piguet is often cited by papers focused on Liver Disease Diagnosis and Treatment (3 papers), Cancer Mechanisms and Therapy (2 papers) and Liver physiology and pathology (2 papers). A.-C. Piguet collaborates with scholars based in Switzerland, United Kingdom and France. A.-C. Piguet's co-authors include Jean‐François Dufour, Helen L. Reeves, Quentin M. Anstee, Ann K. Daly, Christopher P. Day, Julian Leathart, Alastair D. Burt, Liu Yl, Gillian Patman and Vlad Ratziu and has published in prestigious journals such as Nature Communications, Gastroenterology and Journal of Hepatology.

In The Last Decade

A.-C. Piguet

7 papers receiving 985 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

2014 454 citations Yang‐Lin Liu, Helen L. Reeves et al. Nature Communications profile →
Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma

2014 404 citations Liu Yl, Gillian Patman et al. Journal of Hepatology profile →

Peers

A.-C. Piguet

EPIDE

HEPAT

EDM

CB

MB

Sara Badiali Italy

B. Mccolgan United States

Ēriks Šmagris United States

John Brooling United States

Jana Hundertmark Germany

Aastha Jindal Italy

Yosuke Aihara Japan

Enara Arretxe Spain

Roman Liebe Germany

Yoshiyuki Sakamaki Japan

Sara Badiali Italy

A.-C. Piguet

499 ×0.6

EPIDE

171 ×0.4

HEPAT

264 ×0.7

EDM

120 ×0.6

CB

115 ×0.7

MB

Citations per year, relative to A.-C. Piguet A.-C. Piguet (= 1×) peers Sara Badiali

Countries citing papers authored by A.-C. Piguet

Since Specialization

Citations

This map shows the geographic impact of A.-C. Piguet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.-C. Piguet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.-C. Piguet more than expected).

Fields of papers citing papers by A.-C. Piguet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.-C. Piguet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.-C. Piguet. The network helps show where A.-C. Piguet may publish in the future.

Co-authorship network of co-authors of A.-C. Piguet

This figure shows the co-authorship network connecting the top 25 collaborators of A.-C. Piguet. A scholar is included among the top collaborators of A.-C. Piguet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.-C. Piguet. A.-C. Piguet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Piguet, A.-C., Jacek Jemielity, Joanna Kowalska, et al.. (2014). Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma. Nanomedicine Nanotechnology Biology and Medicine. 11(1). 67–76. 35 indexed citations

2.

Liu, Yang‐Lin, Helen L. Reeves, Alastair D. Burt, et al.. (2014). TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nature Communications. 5(1). 4309–4309. 454 indexed citations breakdown →

3.

Yl, Liu, Gillian Patman, Julian Leathart, et al.. (2014). Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. Journal of Hepatology. 61(1). 75–81. 404 indexed citations breakdown →

4.

Gottardi, Andrea De, Vanessa Banz, Federico Storni, et al.. (2014). P523 SAFETY AND EFFICACY OF AN AUTOMATED LOW FLOW ASCITES (ALFA) PUMP IN CIRRHOTIC PATIENTS WITH REFRACTORY ASCITES. Journal of Hepatology. 60(1). S244–S244. 2 indexed citations

5.

Majumder, Syamantak, A.-C. Piguet, Jean‐François Dufour, & Suvro Chatterjee. (2013). Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. European Journal of Pharmacology. 705(1-3). 86–95. 37 indexed citations

6.

Piguet, A.-C., Syamantak Majumder, V. Uma Maheswari, et al.. (2013). Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities. Clinical Science. 126(11). 775–791. 19 indexed citations

7.

Martin, Juliette, Fabrice Magnino, Karin Schmidt, et al.. (2006). Hint2, A Mitochondrial Apoptotic Sensitizer Down-Regulated in Hepatocellular Carcinoma. Gastroenterology. 130(7). 2179–2188. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact